ArticleScientific reports2026
A field polymerizing hydrogel enables simultaneous antimicrobial, hemostatic, and analgesic delivery in traumatic wounds.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Traumatic injuries in resource-limited settings, such as remote, rural, or disaster-affected environments, require wound care solutions that can effectively address hemorrhage, infection, and pain outside of traditional clinical infrastructure. We developed a field-polymerizable hydrogel wound dressing capable of delivering tranexamic acid (hemostatic), vancomycin and tobramycin (broad-spectrum antibiotics), and lidocaine (analgesic) directly to the site of injury. Using computational modeling, we designed a lightweight, rugged hydrogel that polymerizes rapidly with potable water and conforms to irregular wound beds. The system demonstrated burst release of hemostatic and analgesic agents and sustained antibiotic release over four days. In vitro and in vivo testing confirmed the hydrogel’s ability to stabilize clots, prevent fibrinolysis, and eradicate polymicrobial gram-positive and gram-negative bacterial infections in a murine model of open fracture. Large animal studies further validated its translational potential in a large, complex wound. This modular, multifunctional platform provides a field-ready solution for wound management in austere environments, with the potential to reduce infection, control bleeding, and improve wound stabilization when access to definitive care is delayed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.